FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Completed · Not applicable

Conditions studied: Glioblastoma

In brief

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Key facts

Study ID

NCT02902757

Run by

Jonsson Comprehensive Cancer Center

People needed

7

Starts

2015-08-25

Expected to finish

2025-01-29

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically proven high grade glioma
• Intention to start therapy

You may not qualify if…

• Severe psychiatric illness
• Inability to give written consent
• Breast feeding / pregnancy

Where it is running

• UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.